Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia

    Access Status
    Fulltext not available
    Authors
    Hellard, M.
    Jenkinson, R.
    Higgs, Peter
    Stoové, M.
    Sacks-Davis, R.
    Gold, J.
    Hickman, M.
    Vickerman, P.
    Martin, N.
    Date
    2012
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Hellard, M. and Jenkinson, R. and Higgs, P. and Stoové, M. and Sacks-Davis, R. and Gold, J. and Hickman, M. et al. 2012. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Medical Journal of Australia. 196 (10): pp. 638-641.
    Source Title
    Medical Journal of Australia
    DOI
    10.5694/mja11.10981
    ISSN
    0025-729X
    School
    National Drug Research Institute (NDRI)
    URI
    http://hdl.handle.net/20.500.11937/63528
    Collection
    • Curtin Research Publications
    Abstract

    Objectives: To develop a mathematical model to project the potential impact of hepatitis C virus (HCV) treatment on HCV infection prevalence among people who inject drugs (PWID). Design and setting: An existing model of HCV transmission among PWID was parameterised using data from Victoria, Australia, including specific parameter estimates of the number of people who are currently active injecting drug users, average duration of injecting, chronic HCV infection prevalence among PWID, annual mortality, and annual HCV treatment rate. We also explored the impact of prevalence uncertainty, program scale-up, and new treatments. Main outcome measure: Prevalence of chronic HCV infection among people who are currently active injecting drug users. Results: With annual treatment rates of 13, 17, or 25 per 1000 PWID, the model predicts relative prevalence reductions of 20%, 30%, and 50%, respectively, within 30 years. If new treatments giving higher sustained viral response rates are available in 5 years, estimated impact is increased by 21%-23% at 15 years, and 17%-38% at 30 years, depending on treatment rates. Conclusions: This model suggests that modest rates of current HCV treatment among PWID in Victoria, Australia could halve HCV infection prevalence among PWID in 30 years. This finding suggests that interventions aimed at increasing access to HCV treatment in community clinics will benefit individual PWID and reduce HCV infection prevalence.

    Related items

    Showing items related by title, author, creator and subject.

    • Hepatitis C transmission and treatment as prevention - The role of the injecting network
      Hellard, M.; McBryde, E.; Sacks Davis, R.; Rolls, D.; Higgs, Peter; Aitken, C.; Thompson, A.; Doyle, J.; Pattison, P.; Robins, G. (2015)
      Background: The hepatitis C virus (HCV) epidemic is a major health issue; in most developed countries it is driven by people who inject drugs (PWID). Injecting networks powerfully influence HCV transmission. In this paper ...
    • The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs
      Hellard, M.; Rolls, D.; Sacks-Davis, R.; Robins, G.; Pattison, P.; Higgs, Peter; Aitken, C.; McBryde, E. (2014)
      With the development of new highly efficacious direct acting antiviral treatments (DAAs) for hepatitis C (HCV), the concept of treatment as prevention is gaining credence. To date the majority of mathematical models assume ...
    • Availability of HIV prevention and treatment services for people who inject drugs: Findings from 21 countries
      Petersen, Z.; Myers-Franchi, Bronwyn ; van Hout, M.C.; Plüddemann, A.; Parry, C. (2013)
      Background: About a third of the global HIV infections outside sub-Saharan Africa are related to injecting drug use (IDU), and this accounts for a growing proportion of persons living with HIV. This paper is a response ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.